Artemis Khatcherian

TL;DR: This data indicates that suppression of Th1 and Th17 cytokines in Psoriasis vulgaris is a pro-inflammatory disease and the relative contribution of interferon, IFN,γ, interleukin and IL‐22 on disease pathogenesis is still unknown.

TL;DR: It is shown that etanercept has early inhibitory effects on a newly appreciated type of T cells: T helper type 17 (Th17) cells, which may be particularly important in driving epidermal activation in psoriatic plaques whereas Th1 cells must also be eliminated for final disease resolution.

TL;DR: Evidence is presented that the IL-23/Th17 axis is largely absent in atopic dermatitis, perhaps accounting for recurrent skin infections in this disease.

TL;DR: Dermal inflammatory dendritic cells in AD and TNF and iNOS-producing DCs in psoriasis, and/or their regulatory products, may be potential targets for future therapeutic interventions.

TL;DR: It is suggested that T cells are the primary target for therapy, but that DCs and a spectrum of type 1 inflammatory genes are coordinately suppressed.